Filing Details
Monopar Therapeutics (NASDAQ:MNPR) filed a Form 8-K with the Securities and Exchange Commission on July 22, 2026, disclosing a material event.
8k filedNASDAQ:MNPR
Monopar Therapeutics (MNPR) Reports Material Event to SEC
Filing Details Monopar Therapeutics (NASDAQ:MNPR) filed a Form 8-K with the Securities and Exchange Commission on July 22, 2026, disclosing a material event. Market Context…
Market Context
Monopar Therapeutics's stock currently trades at $112.48 with a market capitalization of $514.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Monopar Therapeutics's stock.
All SEC filings for Monopar Therapeutics are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MNPR Stock Page
Frequently Asked Questions
Where can I read MNPR's SEC filings?
Browse all filings on our MNPR SEC filings page.
What types of SEC filings does Monopar Therapeutics file?
Public companies like Monopar Therapeutics file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.